Ubs Group Ag Editas Medicine, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 410,609 shares of EDIT stock, worth $492,730. This represents 0.0% of its overall portfolio holdings.

Number of Shares

410,609

Previous 342,121 20.02%

Holding current value

$492,730

Previous $1.6 Million 12.34%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $232,174 - $408,188	68,488 Added 20.02%	410,609 $1.4 Million
Q2 2024 Aug 13, 2024	SELL	$4.67 - $7.28 $1.19 Million - $1.85 Million	-253,844 Reduced 42.59%	342,121 $1.6 Million
Q1 2024 May 13, 2024	BUY	$7.03 - $11.07 $3.18 Million - $5 Million	451,956 Added 313.84%	595,965 $4.42 Million
Q4 2023 Feb 09, 2024	BUY	$6.25 - $11.11 $219,793 - $390,705	35,167 Added 32.31%	144,009 $1.46 Million
Q3 2023 Nov 09, 2023	SELL	$6.92 - $9.31 $531,449 - $714,998	-76,799 Reduced 41.37%	108,842 $848,000
Q2 2023 Aug 11, 2023	SELL	$6.36 - $11.47 $1.99 Million - $3.58 Million	-312,223 Reduced 62.71%	185,641 $1.53 Million
Q1 2023 May 12, 2023	BUY	$7.03 - $11.53 $638,675 - $1.05 Million	90,850 Added 22.32%	497,864 $3.61 Million
Q4 2022 Feb 08, 2023	BUY	$8.32 - $13.21 $2.65 Million - $4.2 Million	318,113 Added 357.83%	407,014 $3.61 Million
Q3 2022 Nov 10, 2022	SELL	$12.16 - $19.42 $2.33 Million - $3.73 Million	-191,963 Reduced 68.35%	88,901 $1.09 Million
Q2 2022 Aug 10, 2022	BUY	$9.99 - $21.35 $392,417 - $838,649	39,281 Added 16.26%	280,864 $3.32 Million
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $1.41 Million - $2.77 Million	100,148 Added 70.81%	241,583 $4.6 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $1.22 Million - $1.86 Million	45,839 Added 47.95%	141,435 $3.76 Million
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $190,263 - $353,394	-4,845 Reduced 4.82%	95,596 $3.93 Million
Q2 2021 Aug 13, 2021	BUY	$31.29 - $56.64 $1.35 Million - $2.44 Million	43,110 Added 75.19%	100,441 $5.69 Million
Q1 2021 May 12, 2021	SELL	$39.71 - $90.58 $1.22 Million - $2.79 Million	-30,804 Reduced 34.95%	57,331 $2.41 Million
Q4 2020 Feb 11, 2021	BUY	$27.07 - $84.35 $699,001 - $2.18 Million	25,822 Added 41.44%	88,135 $6.18 Million
Q3 2020 Nov 12, 2020	SELL	$28.06 - $37.16 $193,754 - $256,589	-6,905 Reduced 9.98%	62,313 $1.75 Million
Q2 2020 Jul 31, 2020	BUY	$18.5 - $34.34 $233,137 - $432,752	12,602 Added 22.26%	69,218 $2.05 Million
Q1 2020 May 01, 2020	SELL	$14.88 - $32.78 $607,386 - $1.34 Million	-40,819 Reduced 41.89%	56,616 $1.12 Million
Q4 2019 Feb 14, 2020	SELL	$19.49 - $32.63 $2.74 Million - $4.59 Million	-140,570 Reduced 59.06%	97,435 $2.89 Million
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $2.7 Million - $3.22 Million	120,159 Added 101.96%	238,005 $5.41 Million
Q2 2019 Aug 14, 2019	SELL	$20.48 - $27.76 $213,688 - $289,647	-10,434 Reduced 8.13%	117,846 $2.92 Million
Q1 2019 May 14, 2019	BUY	$19.43 - $26.41 $556,941 - $757,016	28,664 Added 28.77%	128,280 $3.14 Million
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $556,086 - $971,852	-30,571 Reduced 23.48%	99,616 $2.27 Million
Q3 2018 Nov 14, 2018	BUY	$27.65 - $38.39 $998,247 - $1.39 Million	36,103 Added 38.37%	130,187 $4.14 Million
Q2 2018 Aug 14, 2018	SELL	$31.4 - $41.01 $3.77 Million - $4.92 Million	-119,954 Reduced 56.04%	94,084 $3.37 Million
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $3.07 Million - $4.54 Million	102,947 Added 92.67%	214,038 $7.1 Million
Q4 2017 Feb 14, 2018	SELL	$21.89 - $31.34 $945,910 - $1.35 Million	-43,212 Reduced 28.0%	111,091 $3.41 Million
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $991,239 - $1.51 Million	62,697 Added 68.44%	154,303 $3.71 Million
Q2 2017 Aug 14, 2017	BUY	N/A	13,389 Added 17.12%	91,606 $1.54 Million
Q1 2017 Nov 14, 2017	BUY	N/A	78,217	78,217 $1.75 Million

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $82.5M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account